#BEGIN_DRUGCARD DB03475

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
45265

# Chemical_Formula:
C18H26N2O5

# Chemical_IUPAC_Name:
4-[2,2-bis(hydroxymethyl)-5-oxopyrrolidin-1-yl]-3-[(pentan-3-yl)amino]benzoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1-[4-Carboxy-2-(3-Pentylamino)Phenyl]-5,5'-Di(Hydroxymethyl)Pyrrolidin-2-One

# HET_ID:
RA2

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C18H26N2O5/c1-3-13(4-2)19-14-9-12(17(24)25)5-6-15(14)20-16(23)7-8-18(20,10-21)11-22/h5-6,9,13,19,21-22H,3-4,7-8,10-11H2,1-2H3,(H,24,25)

# InChI_Key:
InChIKey=BNIJJJRESBVRNB-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3475

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
350.4094

# Molecular_Weight_Mono:
350.184171952

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1B9V

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.64

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
1.47e+00 g/l

# Primary_Accession_No:
DB03475

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
444508

# PubChem_Substance_ID:
46505361

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02752

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCC(CC)NC1=CC(=CC=C1N1C(=O)CCC1(CO)CO)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:18 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Virion
apical cell membrane
single-pass type II membrane protein (
virion membrane. Cell membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
J02095

# Drug_Target_1_GenBank_ID_Protein:
325236

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
NA

# Drug_Target_1_Gene_Sequence:
>1401 bp
ATGCTACCTTCAACTGTACAAACATTAACCCTATTACTCACATCAGGGGGAGTATTATTA
TCACTATATGTGTCAGCCTCATTGTCATACTTATTGTATTCGGATGTATTGCTAAAATTT
TCATCAACAAAAACAACTGCACCAACAATGTCATTAGAGTGCACAAACGCATCAAATGCC
CAGACTGTGAACCATTCTGCAACAAAAGAGATGACATTTCCACCCCCAGAGCCGGAGTGG
ACATACCCTCGTTTATCTTGCCAGGGCTCAACCTTTCAGAAGGCACTCCTAATTAGCCCT
CATAGGTTCGGAGAGATCAAAGGAAACTCAGCTCCCTTGATAATAAGAGAACCTTTTGTT
GCTTGTGGACCAAAAGAATGCAGACACTTTGCTCTGACCCATTATGCAGCTCAGCCGGGG
GGATACTACAATGGAACAAGAAAGGACAGAAACAAGCTGAGGCATCTAGTATCAGTCAAA
TTGGGAAAAATCCCAACTGTGGAAAACTCCATTTTCCACATGGCAGCTTGGAGCGGATCC
GCATGCCATGATGGTAGAGAATGGACATATATCGGAGTTGATGGTCCTGACAATGATGCA
TTGGTCAAAATAAAATATGGAGAAGCATATACTGACACATATCATTCCTATGCACACAAC
ATCCTAAGAACACAAGAAAGTGCCTGCAATTGCATCGGGGGAGATTGTTATCTTATGATA
ACAGACGGCTCAGCTTCAGGAATTAGTAAATGCAGATTTCTTAAAATTAGAGAGGGTCGA
ATAATAAAAGAAATACTTCCAACAGGAAGAGTGGAGCACACTGAAGAGTGCACATGCGGG
TTCGCCAGCAATAAAACCATAGAATGTGCCTGTAGAGACAACAGTTACACAGCAAAAAGA
CCCTTTGTCAAATTAAATGTGGAAACTGATACAGCTGAAATAAGATTGATGTGCACAAAG
ACTTATCTAGACACTCCCAGACCGGATGATGGAAGCATAGCAGGGCCTTGCGAATCTAAT
GGAGACAAGTGGCTTGGAGGCATCAAAGGAGGATTCGTCCATCAAAGAATGGCATCTAAG
ATTGGAAGATGGTACTCCCGAACGATGTCTAAAACTAACAGAATGGGGATGGAACTGTAT
GTAAAGTATGATGGTGACCCATGGACTGACAGTGATGCTCTTACTCTTAGTGGAGTAATG
GTTTCCATAGAAGAACCTGGTTGGTATTCTTTTGGCTTCGAAATAAAGGACAAGAAATGT
GATGTCCCTTGTATTGGGATAGAGATGGTACACGATGGTGGAAAAGATACTTGGCATTCA
GCTGCAACAGCCATTTACTGTTTGATGGGCTCAGGACAATTGCTATGGGACACTGTCACA
GGCGTTGATATGGCTTTATAA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
10547289	Finley JB, Atigadda VR, Duarte F, Zhao JJ, Brouillette WJ, Air GM, Luo M: Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site. J Mol Biol. 1999 Nov 12;293(5):1107-19.
6294654	Shaw MW, Lamb RA, Erickson BW, Briedis DJ, Choppin PW: Complete nucleotide sequence of the neuraminidase gene of influenza B virus. Proc Natl Acad Sci U S A. 1982 Nov;79(22):6817-21.
7880809	Jedrzejas MJ, Singh S, Brouillette WJ, Laver WG, Air GM, Luo M: Structures of aromatic inhibitors of influenza virus neuraminidase. Biochemistry. 1995 Mar 14;34(10):3144-51.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3519

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
51442

# Drug_Target_1_Name:
Neuraminidase

# Drug_Target_1_Number_of_Residues:
466

# Drug_Target_1_PDB_ID:
1INF

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00064	Neur

# Drug_Target_1_Protein_Sequence:
>Neuraminidase
MLPSTVQTLTLLLTSGGVLLSLYVSASLSYLLYSDVLLKFSSTKTTAPTMSLECTNASNA
QTVNHSATKEMTFPPPEPEWTYPRLSCQGSTFQKALLISPHRFGEIKGNSAPLIIREPFV
ACGPKECRHFALTHYAAQPGGYYNGTRKDRNKLRHLVSVKLGKIPTVENSIFHMAAWSGS
ACHDGREWTYIGVDGPDNDALVKIKYGEAYTDTYHSYAHNILRTQESACNCIGGDCYLMI
TDGSASGISKCRFLKIREGRIIKEILPTGRVEHTEECTCGFASNKTIECACRDNSYTAKR
PFVKLNVETDTAEIRLMCTKTYLDTPRPDDGSIAGPCESNGDKWLGGIKGGFVHQRMASK
IGRWYSRTMSKTNRMGMELYVKYDGDPWTDSDALTLSGVMVSIEEPGWYSFGFEIKDKKC
DVPCIGIEMVHDGGKDTWHSAATAIYCLMGSGQLLWDTVTGVDMAL

# Drug_Target_1_Reaction:
Hydrolysis of alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)- glycosidic linkages of terminal sialic acid residues in oligosaccharides, glycoproteins, glycolipids, colominic acid and synthetic substrates ALL_REAC (other) R03491 R04018 R04634 R04650 R05115 R05117 R05996(G) R05998(G) R05999(G) R06012(G) R06147(G) R06253(G) INHIBITOR 2-Deoxy-2,3-dehydro-N-acetylneuraminic acid

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus release. Additionally helps virus spread through the circulation by further removing sialic acids from the cell surface. These cleavages prevent self-aggregation and ensure the efficient spread of the progeny virus from cell to cell. Otherwise, infection would be limited to one round of replication. Described as a receptor-destroying enzyme because it cleaves a terminal sialic acid from the cellular receptors. May facilitate viral invasion of the upper airways by cleaving the sialic acid moities on the mucin of the airway epithelial cells

# Drug_Target_1_SwissProt_ID:
P03474

# Drug_Target_1_SwissProt_Name:
NRAM_INBLE

# Drug_Target_1_Synonyms:
EC 3.2.1.18

# Drug_Target_1_Theoretical_pI:
7.24

# Drug_Target_1_Transmembrane_Regions:
7-35

#END_DRUGCARD DB03475
